When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Lenacapavir - Wikipedia

   en.wikipedia.org/wiki/Lenacapavir

   Lenacapavir was approved for medical treatment in the European Union in August 2022, [10] [12] in Canada in November 2022, [5] [6] and in the United States in December 2022. [9] [11] [13] [14] It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration (FDA) for treating HIV/AIDS. [11] [15]

3. U.S. FDA approves Gilead's long-acting HIV drug Sunlenca - AOL

   www.aol.com/lifestyle/u-fda-approves-gileads...

   Gilead's Sunlenca, whose common name is lenacapavir, is given once every six months as an injection, but will be in addition to the current treatment regimen of patients. ... U.S. FDA approves ...

4. An injectable HIV-prevention drug is highly effective — but ...

   www.aol.com/news/injectable-hiv-prevention-drug...

   Gilead plans to submit lenacapavir for approval for use as PrEP to the Food and Drug Administration by the end of the year. So this powerful new HIV-prevention tool could hit the U.S. market by ...

5. Gilead's long-acting HIV drug superior to daily pill Truvada ...

   www.aol.com/news/gileads-long-acting-hiv-drug...

   Lenacapavir, branded as Sunlenca, gained U.S. approval in 2022 as a treatment for heavily pre-treated HIV patients. Baeten said that lenacapavir could be approved for PrEP by the end of next year.

6. Woman opens up about losing 123 pounds with new weight loss ...

   www.aol.com/news/fda-approves-weight-loss-drug...

   On Nov. 8, the U.S. Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound, which, according to clinical trials, helped participants lose up to 52 pounds in 16 months.

7. Pre-exposure prophylaxis for HIV prevention - Wikipedia

   en.wikipedia.org/wiki/Pre-exposure_prophylaxis...

   In 2012, the FDA approved the drug for use as pre-exposure prophylaxis (PrEP), based on growing evidence that the drug was safe and effective at preventing HIV in populations at increased risk of infection. [41] The FDA has approved two additional medications for PrEP since then, approving Descovy in 2019 and Cabotegravir (Apretude) in 2021. [4 ...